Loading
Gynaecologic oncologist who co-led KEYNOTE-826, innovaTV 301 and KEYNOTE-A18, the trials that rebuilt cervical cancer treatment.
Bradley Monk (GOG Partners) was a lead investigator of GOG 240, which established bevacizumab in advanced cervical cancer, and co-led KEYNOTE-826, innovaTV 301 (tisotumab vedotin) and KEYNOTE-A18, together the three practice-changing cervical cancer trials of the past five years. He co-leads the GOG Partners industry-collaboration programme and has led ovarian PARP inhibitor trials including ATHENA.
Shares innovaTV 301 / ENGOT-cx12 / GOG-3057, Tissue factor, Tisotumab vedotin, Cervical cancer and the tags cervical, ovarian, cooperative-group.
Shares KEYNOTE-826, VEGF / VEGFR, PD-1, Cervical cancer and the tag cervical.
Shares KEYNOTE-A18 / ENGOT-cx11 / GOG-3047, PD-1, Cervical cancer, Ovarian cancer and the tag cervical.
Shares Cervical cancer and the tags cervical, cooperative-group.
Shares Ovarian cancer and the tags ovarian, cooperative-group.
Shares KEYNOTE-A18 / ENGOT-cx11 / GOG-3047, Cervical cancer, Antibody-drug conjugate (ADC), Ovarian cancer and the tag cooperative-group.
Shares Cervical cancer, Ovarian cancer and the tag cooperative-group.
Shares Tissue factor, Tisotumab vedotin, Cervical cancer.